NCT02055690 2021-05-17
PAZOFOS
The Christie NHS Foundation Trust
Phase 1/2 Terminated
Clinical Trials
13 trialsNCT03014297 2019-08-08
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
University of Kentucky
Phase 1 Terminated
NCT02279602 2018-04-17
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
Mateon Therapeutics
Phase 2 Completed
NCT02132468 2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2 Completed
NCT00653939 2015-02-09
FALCON
Mateon Therapeutics
Phase 2 Completed
NCT00507429 2014-06-09
FACT
Mateon Therapeutics
Phase 2/3 Terminated
NCT01701349 2014-05-01
FACT2
Mateon Therapeutics
Phase 3 Withdrawn
NCT00003768 2014-01-07
Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00003698 2013-12-19
Chemotherapy in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00113438 2011-11-01
Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
Mateon Therapeutics
Phase 2 Completed
NCT00395434 2011-10-31
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
Mateon Therapeutics
Phase 1 Completed
NCT00060242 2010-06-11
Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00077103 2010-06-11
Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
Case Comprehensive Cancer Center
Phase 1/2 Terminated